کد خبر: ۳۶۴۰
تاریخ انتشار: ۲۲ آبان ۱۳۹۵ - ۱۰:۲۸
بیزینس مانیتور

BMI Industry View

BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical market. Underlying issues regarding the operating environment will prevent an immediate uptick in multinational drugmaker interest; rather, this will be a gradual process. Nevertheless, there has been a notable boost in international cooperation with European counterparts in particular over the past six months. This will support the Iranian government's aim to attract greater direct investment from foreign pharmaceutical companies.

 صنعت داروسازی و بهداشت در ایران1


Headline Expenditure Projections

Pharmaceuticals: IRR69.55trn (USD1.93bn) in 2015 to IRR79.49trn (USD1.99bn) in 2016; +14.3% in local currency terms and +2.9% in US dollar terms. Forecast downgraded from previous quarter.

Healthcare: IRR800.60trn (USD22.24bn) in 2015 to IRR900.81trn (USD22.52bn) in 2016; +12.5% in local currency terms and +1.3% in US dollar terms. Forecast upgraded from previous quarter.

 صنعت داروسازی و بهداشت در ایران2


Risk/Reward Index

Iran scores 40.4 out of 100 in terms of its attractiveness as a destination to launch innovative pharmaceuticals in Q416, maintaining its score from the previous quarter, according to BMI's Risk/Reward Index. Iran's position in the index remains stationary at 15th out of 31 countries in the Middle East and Africa region. Its overall score currently sits exactly at the regional average of 40.4.

 صنعت داروسازی و بهداشت در ایران3

Generally speaking, Iran benefits from a large and growing population and relatively widespread access to healthcare services. However, its regulatory regime - including intellectual property rights and economic…

سمیتئاتر